glp-1 liver fibrosis For patients with metabolic dysfunction–associated steatohepatitis and fibrosis, survodutide, a dual agonist of the glucagon and receptors, may confer clinical advantages. Research findings are summarized in a new Quick Take Blog | Vitali-T Clinic Subscription Product Jars:4 Jars

glp-1 liver fibrosis For patients with metabolic dysfunction–associated steatohepatitis and fibrosis, survodutide, a dual agonist of the glucagon and receptors, may confer clinical advantages. Research findings are summarized in a new Quick Take Blog | Vitali-T Clinic Subscription Product Jars:4 Jars

Blog | Vitali-T Clinic

2024;16 doi: 10.7759/cureus.52564

Subscription Product

Jars:4 Jars

Key facts about GLP-1-related gastroparesis: How it happens: GLP-1 drugs slow gastric emptying as part of their mechanism, but this effect becomes excessive in some people Who’s at risk: Those with pre-existing digestive disorders, prior gastric surgery, long-standing diabetes, or elderly patients face higher risk Timeline: Symptoms can appear at any point during treatment, especially during dose increases Reversibility: Most cases improve after dose reduction or medication discontinuation, with recovery taking days to several months Management options: Dietary changes (smaller, low-fat meals), slower dose escalation, supportive medications, or temporary drug cessation Seek immediate medical attention for severe vomiting, dehydration signs, intense abdominal pain, or blood in vomit or stool